Örs Ferenczi
Örs Ferenczi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Botond Bukovszky
Department of Oncology, Semmelweis University, Budapest, Hungary
1 shared publication Csaba Polgár
Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oncology, Semmelweis University, Budapest, Hungary
1 shared publication- Csaba Polgár
Department of Radiotherapy, Semmelweis University, 1085 Budapest, Hungary
1 shared publication - Erika Tóth
Department of Surgical and Molecular Pathology, Centre of Tumour Pathology National Institute of Oncology Budapest Hungary
1 shared publication Ferenc Oberna
Multidisciplinary Center of Head and Neck Tumours, National Institute of Oncology, Budapest, Hungary
1 shared publication- Ferenc Oberna
National Institute of Oncology, Multidisciplinary Head and Neck Cancer Center, 1124 Budapest, Hungary
1 shared publication
Latest Publications
- Open Access
- 25 June 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (13) , 4255
Malignant Transformation and Long-Term Outcome of Oral and Laryngeal Leukoplakia
Background: Oral or laryngeal leukoplakia has an increased risk for malignant transformation but the risk of the two anatomical sites has not been compared to each other yet. Materials and Methods: Clinical data of 253 patients with leukoplakia (oral = 221 or laryngeal = 32) enrolled from January 1996 to January 2022 were analyzed. One hundred and seventy underwent biopsy and 83 did not. The mean follow-up time was 148.8 months. Risk factors for the malignant transformation of leukoplakia were identified using Cox proportional hazard models. Results: In the oral or laryngeal group, the rate of cancer was 21.7% and 50% (p = 0.002), respectively. The 10-year estimated malignant transformation was 15.1% and 42% (p < 0.0001), respectively. The laryngeal group had an increased risk of malignant transformation (p < 0.0001). The 5-year estimated survival with leukoplakia-associated cancer for the oral or laryngeal group was 40.9% and 61.1% (p = 0.337), respectively. Independent predictors of malignant transformation in the oral group were dysplasia and the grade of dysplasia of the leukoplakia, and in the laryngeal group, dysplasia had a significant impact. The malignant transformation rate was low for oral patients without biopsy or with no dysplasia, 3.9% and 5.1%, respectively. The malignant transformation occurred over 10 years. Conclusions: Patients with dysplastic leukoplakia have an increased risk of malignant transformation, but the risk is higher with laryngeal than with oral leukoplakia. There is no significant difference between the groups regarding survival with leukoplakia-associated cancer. Oral patients with no dysplastic lesions have a low risk of malignant transformation. A complete excision and long-term follow up are suggested for high-risk patients to diagnose cancer in an early stage and to control late (over 10 years) malignant events.
- 25 June 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (13) , 4255
Open AccessMalignant Transformation and Long-Term Outcome of Oral and Laryngeal Leukoplakia
Background: Oral or laryngeal leukoplakia has an increased risk for malignant transformation but the risk of the two anatomical sites has not been compared to each other yet. Materials and Methods: Clinical data of 253 patients with leukoplakia (oral = 221 or laryngeal = 32) enrolled from January 1996 to January 2022 were analyzed. One hundred and seventy underwent biopsy and 83 did not. The mean follow-up time was 148.8 months. Risk factors for the malignant transformation of leukoplakia were identified using Cox proportional hazard models. Results: In the oral or laryngeal group, the rate of cancer was 21.7% and 50% (p = 0.002), respectively. The 10-year estimated malignant transformation was 15.1% and 42% (p < 0.0001), respectively. The laryngeal group had an increased risk of malignant transformation (p < 0.0001). The 5-year estimated survival with leukoplakia-associated cancer for the oral or laryngeal group was 40.9% and 61.1% (p = 0.337), respectively. Independent predictors of malignant transformation in the oral group were dysplasia and the grade of dysplasia of the leukoplakia, and in the laryngeal group, dysplasia had a significant impact. The malignant transformation rate was low for oral patients without biopsy or with no dysplasia, 3.9% and 5.1%, respectively. The malignant transformation occurred over 10 years. Conclusions: Patients with dysplastic leukoplakia have an increased risk of malignant transformation, but the risk is higher with laryngeal than with oral leukoplakia. There is no significant difference between the groups regarding survival with leukoplakia-associated cancer. Oral patients with no dysplastic lesions have a low risk of malignant transformation. A complete excision and long-term follow up are suggested for high-risk patients to diagnose cancer in an early stage and to control late (over 10 years) malignant events.
- Open Access
- 12 September 2021
- Published by Akademiai Kiado Zrt. in Orvosi Hetilap
- Vol. 162 (37) , 1471-1479
A brachytherapia szerepe az ajak-szájüregi daganatok kuratív ellátásában
Összefoglaló. A szájüregi daganatok kuratív kezelésében az elsődlegesen választandó műtét mellett a sugárterápiának is jelentős szerepe van. A lokális tumormentesség biztosításához azonban dóziseszkaláció szükséges. Ennek külső besugárzással való megvalósítása a környező normálszövetek fölösleges dózisterhelésével és az ebből következő mellékhatások előfordulásának emelkedésével jár. A brachytherapia (BT) – amelynek során radioaktív sugárforrást/sugárforrásokat juttatunk a tumorba vagy annak közelébe – lehetővé teszi a helyileg magasabb dózis leadását a környező ép szövetek kímélésével. A BT a korai, T1–2N0 stádiumú szájüregi tumoroknál – kedvező prognosztikai faktorok mellett – akár kizárólagosan vagy mint posztoperatíve egyedül alkalmazott terápiás modalitás jön szóba. Kedvezőtlenebb prognózis esetén vagy előrehaladottabb stádiumban (T3–4 vagy N+) a műtétet és/vagy a percutan irradiációt kiegészítő eljárásként alkalmazható kedvező sugárfizikai tulajdonságai miatt. A kis dózisteljesítményű (low-dose-rate, LDR) BT-t már évtizedek óta alkalmazzák a terápiában, de ezt kezdi kiszorítani a nagy dózisteljesítményű (high-dose-rate, HDR), illetve a pulzáló dózisteljesítményű (pulse-dose-rate, PDR) BT. A jelen áttekintő tanulmány célja irodalmi adatok alapján a BT szerepének és indikációjának ismertetése a szájüregi daganatok kuratív kezelésében, alrégiókra lebontva. Orv Hetil. 2021; 162(37): 1471–1479. Summary. Radiation therapy plays a significant role in the curative treatment of oral cavity tumors, in addition to the primary choice of surgery. However, dose escalation is required to ensure local tumor control. Its implementation with external irradiation is accompanied by an unnecessary dose exposure to the surrounding normal tissues and an increase in the incidence of consequent side effects. Brachytherapy (BT), in which a radiation source/sources is/are placed inside or close to the tumor, allows a higher dose to be delivered locally, sparing the surrounding intact tissues. In addition to favorable prognostic factors in early T1–2N0 stage oral cavity tumors, BT is considered either exclusively or as a sole postoperative therapeutic modality. At less favorable prognosis or at a more advanced stage (T3–4 or N+), BT can be used as a complementary procedure after surgery and/or percutaneous irradiation based on its favorable radio-physical properties. Low-dose-rate (LDR) BT has been used in the therapy for decades, but recently it has been replaced by high-dose-rate (HDR) and pulse-dose-rate (PDR) BT. The purpose of this review is to describe the role and indications of BT in the treatment of oral cavity tumors categorized into subregions, based on the literature data. Orv Hetil. 2021; 162(37): 1471–1479.
- 12 September 2021
- Published by Akademiai Kiado Zrt. in Orvosi Hetilap
- Vol. 162 (37) , 1471-1479
Open AccessA brachytherapia szerepe az ajak-szájüregi daganatok kuratív ellátásában
Összefoglaló. A szájüregi daganatok kuratív kezelésében az elsődlegesen választandó műtét mellett a sugárterápiának is jelentős szerepe van. A lokális tumormentesség biztosításához azonban dóziseszkaláció szükséges. Ennek külső besugárzással való megvalósítása a környező normálszövetek fölösleges dózisterhelésével és az ebből következő mellékhatások előfordulásának emelkedésével jár. A brachytherapia (BT) – amelynek során radioaktív sugárforrást/sugárforrásokat juttatunk a tumorba vagy annak közelébe – lehetővé teszi a helyileg magasabb dózis leadását a környező ép szövetek kímélésével. A BT a korai, T1–2N0 stádiumú szájüregi tumoroknál – kedvező prognosztikai faktorok mellett – akár kizárólagosan vagy mint posztoperatíve egyedül alkalmazott terápiás modalitás jön szóba. Kedvezőtlenebb prognózis esetén vagy előrehaladottabb stádiumban (T3–4 vagy N+) a műtétet és/vagy a percutan irradiációt kiegészítő eljárásként alkalmazható kedvező sugárfizikai tulajdonságai miatt. A kis dózisteljesítményű (low-dose-rate, LDR) BT-t már évtizedek óta alkalmazzák a terápiában, de ezt kezdi kiszorítani a nagy dózisteljesítményű (high-dose-rate, HDR), illetve a pulzáló dózisteljesítményű (pulse-dose-rate, PDR) BT. A jelen áttekintő tanulmány célja irodalmi adatok alapján a BT szerepének és indikációjának ismertetése a szájüregi daganatok kuratív kezelésében, alrégiókra lebontva. Orv Hetil. 2021; 162(37): 1471–1479. Summary. Radiation therapy plays a significant role in the curative treatment of oral cavity tumors, in addition to the primary choice of surgery. However, dose escalation is required to ensure local tumor control. Its implementation with external irradiation is accompanied by an unnecessary dose exposure to the surrounding normal tissues and an increase in the incidence of consequent side effects. Brachytherapy (BT), in which a radiation source/sources is/are placed inside or close to the tumor, allows a higher dose to be delivered locally, sparing the surrounding intact tissues. In addition to favorable prognostic factors in early T1–2N0 stage oral cavity tumors, BT is considered either exclusively or as a sole postoperative therapeutic modality. At less favorable prognosis or at a more advanced stage (T3–4 or N+), BT can be used as a complementary procedure after surgery and/or percutaneous irradiation based on its favorable radio-physical properties. Low-dose-rate (LDR) BT has been used in the therapy for decades, but recently it has been replaced by high-dose-rate (HDR) and pulse-dose-rate (PDR) BT. The purpose of this review is to describe the role and indications of BT in the treatment of oral cavity tumors categorized into subregions, based on the literature data. Orv Hetil. 2021; 162(37): 1471–1479.
- 1 March 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (2) , 376-382
Results of postoperative interstitial brachytherapy of resectable floor of mouth tumors
- 1 March 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (2) , 376-382
Results of postoperative interstitial brachytherapy of resectable floor of mouth tumors